Market Herald logo


Be the first with the news that moves the market
  • Appili Therapeutics (APLI) appoints Dr. Juergen Froehlich to its Board of Directors
  • Existing board member Ian Mortimer is appointed as the company’s new Board Chair, replacing Stephen Nicolle
  • Dr. Froehlich has 30 years experience in medical and regulatory affairs
  • Apilli’s shares are currently trading at C$0.89, with a market cap of C$29.89 million

Appili Therapeutics (APLI) has appointed veteran biotech executive Dr. Juergen Froehlich to its Board of Directors.

With 30 years of experience in medical and regulatory affairs, Dr. Froehlich’s career encompasses a broad range of drug development successes; from strategic planning to regulatory interactions across multiple therapeutic areas.

Dr. Froehlich has worked with biologics, peptides, small molecules and RNA therapeutics at some of the world’s largest pharmaceutical and biotechnology companies, including Boehringer Ingelheim, Genentech and Quintiles.

In addition to the appointment of Dr. Froehlich, Appili has announced existing board member Ian Mortimer as the company’s new Board Chair, replacing Stephen Nicolle, who resigned today.

Ian Mortimer has been a member of the Board since 2017, and is also President and Chief Financial Officer of Xenon Pharmaceuticals.

“We are very pleased to welcome Juergen to Appili’s Board. His background will be very valuable as the company advances its clinical portfolio…” said Mr. Mortimer.

“In particular, his successful track record with all stages of clinical development and global regulatory affairs, along with his anti-infective experience, will provide key insights for value creation from Appili’s pipeline.” 

Dr. Froehlich has previously been a key figure in obtaining successful marketing authorizations around the world, including the US, Canada and the EU.

As Chief Medical Officer and Head of Regulatory Affairs at Aradigm Corporation, Dr. Froehlich oversaw a trial program with a liposomal formulation of ciprofloxacin for inhalation.

Designed for patients with non-cystic fibrosis bronchiectasis (NCFBE), it resulted in a New Drug Application and Marketing Authorization Application submission.

He was also invited as a panel member at a US Food and Drug Administration (FDA) workshop in 2018 for inhaled antibiotics in cystic fibrosis and NCFBE.

“I am fully committed to helping companies bring novel treatments to patients with serious unmet medical needs, and I look forward to supporting Appili Therapeutics in this endeavor,” said Dr. Froehlich. 

“I am pleased to share my insights on specific global and local regulatory requirements, clinical-stage planning, and the transition from developmental to commercial activities as the company progresses its portfolio.” 

Appili has granted 140,000 stock options under its Stock Option Plan as part of his new role as director.

The stock options will be exercisable at C$0.815 per share over a period of ten years.

Appili Therapeutics’ shares are currently trading at C$0.89, with a market cap of C$29.89 million.

More From The Market Herald
Neuralink - Founder, Elon Musk.

" Neuralink brain chips approved for human trials

Elon Musk’s Neuralink, a brain implant firm, has received regulatory approval for U.S. human trials.

" BioSyent reports Q1 2023 financial results

BioSyent (TSXV:RX) released its financial results for the three months ended March 31, 2023.

" Highmark Interactive approved for reimbursement services of remote patient monitoring devices

Highmark Interactive (V.HMRK) has been processed for remote patient monitoring and reimbursed by Medicare for those services.

" New data to be highlighted at the world’s top cancer conference

Next week, top health care firms will converge or the biggest cancer conference in the world.